Gastrointestinal Cancer

The FDA has approved 2 zanidatamab-hrii–based regimens following phase 3 results demonstrating significant improvements in progression-free survival.

The FDA-granted priority review raises the possibility of an immunotherapy-first approach that could allow some patients to avoid chemotherapy, radiation, and surgery.

The FDA approved SimpleScreen CRC, a blood-based screening test for average-risk adults aged 45 and older, potentially expanding screening access.

The blood test offers a promising new approach to identify patients who are at high risk for recurrence and guide precision treatment strategies.

The FDA granted Priority Review to the NDA for bezuclastinib plus sunitinib in previously treated advanced gastrointestinal stromal tumors (GIST).

ASCO 2026: Daraxonrasib boosts survival and PFS in metastatic pancreatic cancer vs chemotherapy, with better tolerability and quality-of-life preservation.

Neoadjuvant pembrolizumab in colorectal cancer delivers durable, relapse-free outcomes presurgery, with ctDNA blood tests helping to predict responders.

H. pylori requires diagnosis, antibiotic- and acid-suppression-based therapy, and post-treatment eradication confirmation to prevent gastritis and cancer.

Atebimetinib shows promise in enhancing pancreatic cancer treatment, achieving a 64% survival rate and improving patient quality of life.

A cohort study of over 6 million US veterans revealed a 76% increased risk of pancreatic cancer following chronic hepatitis C infection.

The FDA approved durvalumab with FLOT chemotherapy, revolutionizing treatment for early gastric and gastroesophageal junction cancers, enhancing survival rates.

New research links oral bacteria and fungi to pancreatic cancer risk, suggesting oral microbiota as potential noninvasive biomarkers for early detection.

New research uncovers how smoking accelerates pancreatic cancer progression through immune mechanisms, revealing potential for targeted therapies and improved screening.

Recent advances in GI oncology offer new treatment options for colorectal and pancreatic cancers, enhancing patient care and pharmacist roles in management.

Herzuma shows promising efficacy and safety as a cost-effective biosimilar for treating HER2+ advanced gastric cancer, offering new hope for patients.

Durvalumab continues to demonstrate efficacy in a variety of cancers, with new data from the phase 3 MATTERHORN trial solidifying its use with chemotherapy in gastric cancer.

The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.

Y-90 resin microspheres offer a new option for patients with liver cancer for the treatment of unresectable hepatocellular carcinoma.

At the 2025 Oncology Pharmacists Connect (OPC) meeting, Courtney Cavalieri, PharmD, BCOP, presented clinical trial findings in gastrointestinal (GI) cancers—including colon, gastric, pancreatic, and metastatic colorectal cancer—that highlight the expanding role of immunotherapy and targeted treatments.

The FDA approves retifanlimab for advanced anal cancer, offering new hope with improved survival rates and treatment options for patients.